Fig. 1

Delivery of anti-CTLA4 to tbLN using LDDS elicits robust and consistent tumor inhibitory response. 5 mg/kg a-CTLA4 mAb was administered into the tbLN or the ntbLN using a LDDS or through i.p. on day 4 and 8 post tumor inoculation to unilaterally inoculated MXH10/Mo/lpr mice to determine the optimal drug administration strategy. A. Experiment outline B. Representative in vivo luciferase activity C. Graphical representation of in vivo luciferase activity of the SiLN of individual mice D. Summarized graphical representation of normalized SiLN luciferase activity as a function of time. (C – D: Control, n = 12; tbLN, n = 6; ntbLN, n = 11; i.p., n = 7) E. SiLN weight normalized to mouse body weight (No tumor control, n = 8; Control, n = 6; tbLN, n = 8; ntbLN, n = 7; i.p., n = 4) F. Normalized SiLN volume as on the pre-determined experimental endpoint (Control, n = 11; tbLN, n = 7; ntbLN, n = 11; i.p., n = 6) G. ex vivo luciferase activity of the SiLN, PALN, liver and lung as measured on the pre-determined experimental endpoint (Control, n = 14; tbLN, n = 6; ntbLN, n = 5; i.p., n = 4) H. Complete response rates (Control, n = 6; tbLN, n = 13; ntbLN, n = 9; i.p., n = 7) I. Survival plots of mice (Control, n = 20; tbLN, n = 14; ntbLN, n = 11; i.p., n = 4). Statistical analyses were done using ANOVA with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *P < 0.05, **P < 0.01, and ****P < 0.0001. Data are represented as means ± SEM